Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Trampel KA, Gross KY, O'Reilly D, Melisova A, Salman B, Green S, George SA, Khvorova A, Efimov IR, Efimova T. RNAi-mediated p38d silencing mitigates anthracycline cardiotoxicity in female mice. Am J Physiol Heart Circ Physiol. 2026 May 01; 330(5):H1522-H1539.
-
Rao K, Rao Z, Huang A, Heston S, Wang M, Yildiz-Altay ?, Qutab F, Kwong DA, Gardner HL, Richmond JM, London CA. Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL. Sci Rep. 2026 Mar 17; 16(1).
-
Wen D, Zhang Q, van Agthoven J, Weins A, Rosales IA, Zhou W, Kim T, Vela Parada X, Colvin RB, Pollak MR, Grams ME, Schmidt IM, Waikar SS, Arnaout MA, Rhee EP. Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection. J Am Soc Nephrol. 2026 Apr 01; 37(4):700-712.
-
Gupta A, Maity A, Ndugire W, Chakraborty S, Ghorpade MS, Hirschbiegel CM, Ribbe A, Chakraborty A, Rotello VM. Engineered Lipid Coronas for Gold Nanoparticle-Based Bioorthogonal Catalysis. Nano Lett. 2025 07 09; 25(27):10962-10969.
-
Anderson E, Choi Y, Buchsbaum RJ, Klein A, Ky B, Landsburg D, Durani U, Ruddy KJ, Yu AF, Leong D, Asnani A, Neilan TG, Ganatra S, Bloom M, Barac A, Yang EH, Deswal A, Cheng RK, Weiss M, Evens AM, Kahl B, Friedberg JW, Parsons SK, Upshaw JN. Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Perera L, Brown SM, Silver BB, Tokar EJ, Sinha BK. Ferroptosis Inducers Erastin and RSL3 Enhance Adriamycin and Topotecan Sensitivity in ABCB1/ABCG2-Expressing Tumor Cells. Int J Mol Sci. 2025 Jan 14; 26(2).
-
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
McLinden GP, Avery AC, Gardner HL, Hughes K, Rodday AM, Liang K, London CA. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. J Vet Intern Med. 2024 May-Jun; 38(3):1666-1674.
-
Arun Kumar S, Mishra R, Malempati SC, Bindal P. Primary cardiac large B cell lymphoma. BMJ Case Rep. 2023 Dec 26; 16(12).